ClinicalTrials.gg
TerminatedNCT06961344Updated Nov 6, 2026

An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)

A Phase 2 interventional study of zagociguat 15mg in Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome), sponsored by Tisento Therapeutics. Terminated at 16 sites in 5 countries. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Tisento Therapeutics · Phase 2, Interventional, and Treatment

Why this study was terminated
Terminated based on results from the parent study, which did not meet its primary or secondary efficacy endpoints. The decision was not related to a safety.
Updated Nov 6, 2026Now TerminatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Acidosis, Lactic with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Acidosis, Lactic · United States.

Enrollment
4th of 14
37 · median 29
Started
2025
the only one that year
Phase 2
6 of 19
none open now
Registered
19th of 19
by date
Lead sponsor
2 of 19
Tisento Therapeutics

Among the 19 studies in Acidosis, Lactic with a site in United States, this one is the 4th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2025, is one of 6 in phase 2, and was the 19th registered.

Acidosis, Lactic

48 studies on the registry are indexed under Acidosis, Lactic; 5 are open to participants now.

Browse Acidosis, Lactic studies →

Open to participants now

2 of the 19 studies in Acidosis, Lactic with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Acidosis, Lactic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Acidosis, Lactic with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the long-term safety and tolerability of zagociguat in patients with MELAS who completed study medication treatment in the lead-in study TIS6463-203. TIS6463-204 is evaluating zagociguat in an open-label extension study at the daily dose of 15mg. The study medication is a once daily oral table and will be provided at the clinic and/or shipped to the participant's home. Study assessments will be conducted during clinic visits which will occur at three months and then at six months. Thereafter, clinic visits will occur every six months.

Read the detailed description

On Screening Visit Day -1 (which corresponds to Period 2 Week 12 Visit from lead-in study TIS6463-203), participants will sign the informed consent form, be confirmed eligible for this open-label extension study and undergo Screening Visit assessments. Eligible participants will begin dosing the next day on Day 1 (there is no Day 0) at home. Participants will have a 3-month visit and 6-month study visit at the clinic and thereafter will have a clinic visit every 6 months. Participants should have a Follow-up Visit 4 (+1) weeks after zagociguat discontinuation.

03

Conditions studied

  • Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)

Keywords

  • MELAS
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved form (ICF).
  2. Completed TIS6463-203 treatment through the Period 2 Week 12 Visit.
  3. Agrees to follow lifestyle restrictions.
  4. Other criteria per the protocol.

Exclusion criteria

Exclusion Criteria:

1. Any medical condition or clinical finding that, per investigator judgement, would preclude safe study participation and/or completion of all trial requirements.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Zagociguat 15mg

    Participants receive zagociguat 15 mg once a day (QD) for the duration of the study.

    Drug: zagociguat 15mg

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-emergent Adverse Events (TEAEs)

    TEAEs are any untoward event that may or may not be related to study medication.

    Time frame: Day 1 through the Follow-up for treatment period 4 weeks after last dose of study medication.

07

Study locations

16 sites
  • UC San Diego - Altman Clinical and Translational Research Institute
    La Jolla, California 92037, United States
  • Children's Hospital of Colorado
    Aurora, Colorado 80045, United States
  • Rare Disease Research
    Atlanta, Georgia 30329, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Mount Sinai - Ichan School of Medicine
    New York, New York 10029, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • UT Health Houston
    Houston, Texas 77030, United States
  • Neuroscience Research Australia
    Sydney, New South Wales NSW 2031, Australia
  • Royal Melbourne Hospital
    Melbourne, Victoria 3052, Australia
  • LMU Klinikum, Friedrich-Baur-Institute, Department of Neurology
    Munich, 80336, Germany
  • Neurologic Institute Carlo Besta of Milan
    Milan, 20133, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli
    Rome, 00168, Italy
  • University College London Hospital. The National Hospital for Neurology and Neurosurgery, Centre for Neuromuscular Diseases
    London, WC1N 3BG, United Kingdom
  • The Newcastle upon Tyne NHS Foundation Trust
    Newcastle upon Tyne, NE14LP, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2025 to primary completion in Oct 2026, 14 months.

Primary completion moved twice since we started tracking on Sep 25, 2026: Jul 2028 → Oct 2026, last on Nov 6, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Jul 2028 → Oct 2026, last on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 7, 2025
StartActual
Aug 18, 2025
Primary completionActual
Oct 29, 2026was Jul 2028
CompletionActual
Oct 29, 2026was Jul 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Terminated based on results from the parent study, which did not meet its primary or secondary efficacy endpoints. The decision was not related to a safety.
changed Oct 30, 2026
Primary completion
Jul 2028→Oct 29, 2026
moved 2 times, Oct 30, 2026 – Nov 6, 2026
Study completion
Jul 2028→Oct 29, 2026
moved 2 times, Oct 30, 2026 – Nov 6, 2026
Enrollment
44 (estimated)→37 (actual)
Oct 30, 2026
Show all 4 updates
  1. Nov 6, 2026
    Primary completion Oct 26, 2026→Oct 29, 2026
    Study completion Oct 26, 2026→Oct 29, 2026
  2. Nov 3, 2026
    Why stopped Terminated based on results from the parent study, which did not meet its primary or secondary efficacy endpoints. The decision was not related to a safety.
    + 1 other change: verification date
  3. Oct 30, 2026
    Active, not recruiting→Terminated
    Why stopped On 5 October 2026 the study was terminated based on results from the parent study, which did not meet its primary or secondary efficacy endpoints. The decision was not related to a safety.
    Primary completion Jul 2028→Oct 26, 2026 (now actual)
    Study completion Jul 2028→Oct 26, 2026 (now actual)
    Enrollment 44 (estimated)→37 (actual)
  4. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06961344
Lead sponsor
Tisento Therapeutics
Responsible party
Sponsor
First posted
May 7, 2025
Start date
Aug 18, 2025
Primary completion
Oct 29, 2026
Completion
Oct 29, 2026
Last update
Nov 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zagociguat

Start the discussion